Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Endocrine/metabolic disease

Dyslipidemia

X-box binding protein 1 (XBP1); endoplasmic reticulum to nucleus signaling 1 (ERN1; IRE1)

Studies in mice suggest antagonizing XBP1 or IRE1 could help treat dyslipidemia. In mice fed a high-fat diet, hepatocyte-specific deletion of IRE1, a bifunctional kinase and nuclease that promotes XBP1 activity, or small interfering RNA against Xbp1 decreased triglyceride and cholesterol levels compared with control vector. Next steps include testing IRE1 inhibitors in mice with dyslipidemia.

SciBX 5(42); doi:10.1038/scibx.2012.1111
Published online Oct. 25, 2012

Patent pending for findings in first study; available for licensing

Patent and licensing status undisclosed for findings in second study

So, J.-S. et al. Cell Metab.; published online Oct. 3, 2012;
doi:10.1016/j.cmet.2012.09.004
Contact: Ann-Hwee Lee, Harvard School of Public Health, Boston, Mass.
e-mail:

anl2042@med.cornell.edu

Wang, S. et al. Cell Metab.; published online Oct. 3, 2012;
doi:10.1016/j.cmet.2012.09.003
Contact: Randal J. Kaufman, Sanford-Burnham Medical Research Institute, La Jolla, Calif.
e-mail:

rkaufman@sbmri.org